ADA Scientific Sessions 2025 Abstract

Efficacy and Safety of Tirzepatide Added to Basal Insulin in Chinese Patients with Type 2 Diabetes (SURPASS-CN-INS)

By Lixin Guo, Xiaolin Dong, Jianhua Ma, Jiawei Xu

Trial in peopleInterventions

The paper

Lixin Guo, Xiaolin Dong, Jianhua Ma, Jiawei Xu

Beijing

ADA Scientific Sessions 2025 Abstract, 13 Jun 2025

Presented at ADA Scientific Sessions 2025, poster 730-P

doi.org/10.2337/db25-730-p

Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
Lancet4 Oct 2026
Orforglipron matches insulin glargine on cardiovascular safety